menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

The Pathophysiology of sHPT: Understanding the Calcium-Sensing Receptor Pathway

Program Information
Recommended

Program Information

The Pathophysiology of sHPT: Understanding the Calcium-Sensing Receptor Pathway
RestartResume

Although we don’t hear much about the calcium-sensing receptor, it plays a pivotal role in the development of secondary hyperparathyroidism.

  • Sponsored by

  • Overview

    The calcium-sensing receptor is the key regulator of parathyroid hormone secretion and has a prime role in the development of secondary hyperparathyroidism (sHPT). To learn more about this pathway’s role in sHPT along with key management strategies, Dr. John Russell speaks with nephrologist Dr. Kevin Griffiths and renal dietitian Anna Chambers.

    This promotional, non-CME program is intended for US Health Care Professionals. Kevin Griffiths, MD, MPH, FASN and Anna Chambers, MS, RD, LDN were paid a fee by Amgen for their participation in the program.

                                                                                                                                                           USA-416-80965

  • REFERENCES

    1. Goodman WG, Quarles LD. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int. 2008;74:276-288.
    2. Naveh-Many T, Volovelsky O. Parathyroid cell proliferation in secondary hyperparathyroidism of chronic kidney disease. Int J Mol Sci. 2020;21:4332; doi:10.3390/ijms21124332.
    3. Waziri B, Duarte R, Naicker S. Chronic kidney disease—Mineral and bone disorder (CKD- MBD): current perspectives. Int J Nephrol Renovasc Dis. 2019;12:263-276.
    4. Gorvin CM. Calcium-sensing receptor signaling—how human disease informs biology. Curr Opin Endocr Metab Res. 2021;16:10-18.
    5. Goodman WG. Calcium and phosphorus metabolism in patients who have chronic kidney disease. Med Clin N Am. 2005;89:631-647.
    6. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease—Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1–59.
    7. Block G, Do TP, Collins AJ, et al. Co-trending of parathyroid hormone and phosphate in patients receiving hemodialysis. Clin Nephrol. 2016;85:142-151.
    8. McCann LM, Beto J. Roles of calcium-sensing receptor and vitamin D receptor in the pathophysiology of secondary hyperparathyroidism. J Ren Nutr. 2010;20:141-150.
    9. Bellorin-Font E, Vasquez-Rios G, Martin KJ. Controversies in the management of secondary hyperparathyroidism in chronic kidney disease. Curr Osteoporos Rep. 2019;17:333-342.
    10. Negrea L. Active vitamin D in chronic kidney disease: getting right back where we started from? Kidney Dis(Basel). 2019;59-68.

Programs 8/1/21